Methods for identifying a subject with a cancer eligible for treatment with an inhibitor of a Table 1 molecule, optionally a SRC kinase inhibitor or a MET kinase inhibitor, are provided. The methods comprise testing a biological sample from the subject for a deficiency in EPHB6 receptor levels, wherein the subject is eligible for treatment with an inhibitor of a Table 1 molecule, optionally a SRC kinase inhibitor or a MET kinase inhibitor, if EPHB6 receptor levels in the biological sample are deficient.

The present invention provides a method of inhibiting tumor-mediated immunosuppression in a subject, comprising administering to the subject a therapeutically effective amount of an agent that inhibits the activity of Semaphorin 4D.

The objective of the present invention is to provide a method for simply, inexpensively and accurately assessing, before administering a biological preparation, the therapeutic effect thereof (in particular whether there will be a complete response) or the improvement of symptoms in patients having rheumatoid arthritis.

By using at least one serum concentration selected from the group consisting of sgp130, IP-10, sTNFRI, sTNFRII, GM-CSF, IL-1, 1L-2, IL-5, 1L-6, IL-7, IL-8, 1L-9, IL-10, IL-12, IL-13, IL-15, Eotaxin, VEGF , MCP-1, TNF-, IFN-, FGF basic, PDGF-bb, sIL-6R and MIP-1, the therapeutic effect (improvement of symptoms and possibility of response) of an inflammatory cytokine-targeting biological preparation on a patient having rheumatoid arthritis can be predicted in any type of facility in a simple, inexpensive, and highly accurate manner before administering the biological preparation.

Methods of determining infection type are disclosed. In one embodiment, the method comprises measuring the amount of TRAIL and/or IP10 no more than two days from symptom onset.

The present invention concerns the field of stem cell biology, and in particular relates to a method for producing an isolated bona fide population of mammalian stem cells, and uses of the stem cells thus produced. Human glioblastomas (hGBMs) have now been shown to contain a minor subset of cells bearing the defining features of somatic stem cells (SCs) and the ability to establish, expand and perpetuate these tumors. They are defined stem-like tumor propagating cells (TPCs). This has caused a paradigmatic shift in the way we interpret hGBM physiology, for it identifies TPCs as a major culprit to be tackled for the development of novel therapeutics. It also suggests that studying the regulatory mechanisms of normal neurogenesis may point to specific inhibitors of TPCs.

The present invention relates to methods of diagnosing, predicting and monitoring kidney disorders. In particular, the present invention relates to the diagnosis, prediction and monitoring of kidney disorders by detection of cytokines, cytokine-related compounds and chemokines in urine. The present invention further relates to methods and compositions for assessing the efficacy of agents and interventions used to treat kidney disorders.

An in vitro co-culture system comprising cancer-associated fibroblasts (CAFs) and cancer cells for producing and maintaining cancer stem cells and uses thereof for identifying agents capable of reducing cancer cell stemness. Also disclosed herein are a paracrine network through which CAFs facilitate production and/or maintenance of cancer stem cells and the use of components of such a paracrine network for prognosis purposes and for identifying cancer patients who are likely to respond to certain treatment.

The present invention is directed to a method for identifying an individual who is at risk for developing metastatic liver disease that involves measuring, in a sample isolated from the individual, exosomal levels of one or more markers of metastatic liver disease. Kits for carrying out this method are also disclosed. The present invention also relates to a method of preventing metastatic liver disease in an individual who are at risk for developing the disease that involves administering one or more inhibitors of liver pre-metastatic niche formation.

The invention relates to a method for predicting the clinical response to a therapy based on the administration of mesenchymal stem cells (MSCs) in a patient suffering from an immune-mediated inflammatory disease. The invention also relates to methods of personalised medicine as well as to therapeutic uses of MSCs in a patient suffering from an immune-mediated inflammatory disease.

Provided are a method and means permitting the simultaneous measurement of the reactive properties of more than 10,000 of antigen-stimulated lymphocytes being held on a chip and the separate determination of the states of individual cells. A microwell array comprises multiple wells and a coating layer on one of the principal surfaces of a base member, the wells being of a size permitting the entry of only a single cell into each well. A coating layer of a substance capable of binding to a substance produced by the cells contained in the wells is present on the principal surface around the wells. A method of screening for a target cell, comprises: causing specimen cells and a cell culture broth to be contained in the wells of the above microwell array; immersing the coating layer and the wells in the culture broth and culturing the cells in a state permitting the diffusion of substances in the culture broth from the wells into the coating layer; feeding a label substance binding specifically to a substance produced by a target cell present among the specimen cells onto the coating layer; and detecting the substance produced by the target cell that has bound to the substance in the coating layer by the label substance to specify the target cell.